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ABSTRACT
We investigated the possible clinical correlates between the serum
LH concentration and characteristics of frailty and determined the
presence and concentration of a genetic LH variant in an indepen-
dently living population of elderly men. After exclusion of subjects
with severe mobility problems and signs of dementia, 403 healthy
men (aged 73–94 yr) were randomly selected from a population-based
sample. Total testosterone (T), sex hormone-binding globulin (SHBG),
and leptin were determined by RIA. Non-SHBG-bound T was calcu-
lated. LH and the presence of the genetic LH variant were measured
using immunofluorometric assays. The characteristics of frailty were
leg extensor strength using dynamometry, bone mineral density of
total body and proximal femur, and body composition, including lean
mass and fat mass, measured by dual energy x-ray absorptiometry.
Disability was further assessed by the Modified Health Assessment
Questionnaire and by a measure of physical performance.
LH significantly increased with age and inversely correlated with
T and non-SHBG-bound T. LH was inversely related to muscle
strength and lean mass, and both relations were independent of T. LH
was positively related to self-reported disability (Modified Health
Assessment Questionnaire); 12.5% of the study population was het-
erozygous for the LH variant allele. T levels and the degree of frailty
were not different in the wild-type LH group compared with the
heterozygote LH variant group. A significant positive relation be-
tween LH and fat mass as well as leptin was only present in the
heterozygote LH variant group.
In conclusion, serum LH levels increases with age in independently
living elderly men and correlates inversely with a variety of indicators
of frailty. The observed relation between LH and frailty, independent
of T, suggests that LH reflects serum androgen activity in a different
way than T, possibly reflecting more closely the combined feedback
effect of estrogen and androgen. A difference in biological response
between the two LH forms is suggested, as a difference exists in the
relation between LH and fat mass, respectively, and leptin in the
heterozygote LH variant subjects vs. the wild-type LH subjects.
(J Clin Endocrinol Metab 84: 1334–1339, 1999)
PHYSICAL frailty in the elderly is defined as “a state ofreduced physiological reserves associated with in-
creased susceptibility to disability” (1). Age-related disability
is characterized by generalized weakness, impaired mobility
and balance, and poor endurance. Clinical correlates of phys-
ical frailty include falls, fractures, impairment in activities of
daily living, and loss of independence; falls contribute to 40%
of admissions to nursing homes (2). Falls are significantly
associated with slow gait, poor physical performance, and
lack of muscle strength (3–5).
In a previous study we demonstrated that low testosterone
(T) levels in a population of healthy elderly men were as-
sociated with reduced muscle strength and bone mineral
density and increased fat mass (unpublished data). As a
negative feedback relationship exists between T and LH, the
circulating LH level may also serve as an indicator of frailty.
Recently, a common variant form of LH was detected in
apparently healthy individuals, caused by point mutation-
based substitutions of two amino acids (Trp8Arg and
Ile15Thr) in the LH b-subunit (6–8). Suggestions have been
made that the in vivo bioactivity of the LH variant is lower
than that of the wild-type hormone due to its shorter circu-
latory half-time (9, 10). Raivio et al. (10) suggested that the
occurrence of the variant LH may be a factor contributing to
delayed pubertal tempo in otherwise healthy boys. No data
are available yet describing the presence and bioactivity of
this LH variant in elderly populations.
We investigated serum LH levels in relation to character-
istics of frailty and determined the presence and concentra-
tion of the genetic LH variant in an independently living
population of elderly men. The purpose was to determine
whether any of the variable alterations in pituitary-testicular
function with aging could be related to the occurrence of a
biologically dissimilar variant form of LH.
Subjects and Methods
Subjects
A group of 403 independently living men, aged 73 yr or above,
participated in this study. Participants were recruited by letters of in-
vitation, which were sent to the oldest male inhabitants of Zoetermeer,
a medium-sized town in the midwestern part of The Netherlands. All
participants provided informed consent, and the study was approved by
the medical ethics committee of Erasmus University Hospital Rotter-
dam. Participants were judged sufficiently healthy to participate in the
study when they were physically and mentally able to visit the study
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center independently. No additional health-related eligibility criteria
were used.
Hormone measurements
Blood samples were collected in the morning after an overnight
fast. Serum concentrations of total T (TT; nanomoles per L) and sex
hormone-binding globulin (SHBG; nanomoles per L) were all mea-
sured by RIA using commercial kits (Diagnostic System Laboratories,
Webster, TX). The intraassay coefficients of variation (CVs) were,
respectively, 8.1% and 3.0%. The interassay CVs were, respectively,
10.5% and 4.4%. Non-SHBG-bound T (non-SHBG-T; nanomoles per
L) was calculated according to a method described by So¨dergård et
al. (11). Leptin (micrograms per L) was also measured by RIA (Lilly
Research Laboratories, Giessen, Germany). Albumin (grams per L)
was measured by photometry using a commercial kit (ALB, Boehr-
inger Mannheim, Mannheim, Germany).
LH (international units per L) was measured by an immunofluoro-
metric assay (Delfia, Wallac Oy, Turku, Finland). The LH variant was
recognized after calculation of the ratio of the results of two LH assays.
The Delfia method for LH (LHspec), which uses two LH b-subunit-
specific monoclonal antibodies (mAb) (12, 13), served as a reference
method (assay 2). In the other assay (assay 1), the capture mAb recog-
nizes a conformational epitope present in the wild-type a/b LH dimer
but not in the variant form of LH or the free subunits, and the detection
mAb recognizes an epitope in the a-subunit (6). The ratio of LH values
measured by the two assays (assay 1/assay 2) was used to assess the
variant or wild-type LH status. Three separate categories of this ratio
were obtained: 1) normal ratio (.0.9), 2) low ratio (0.2–0.9), and 3) zero
ratio (,0.15). A normal ratio individual has two wild-type LH alleles,
a low ratio individual is heterozygous for the LH variant allele, and a
zero ratio individual is homozygous for the variant LHb gene, as con-
firmed by DNA analysis (9, 14, 15). The sensitivity of the two immun-
ofluorometric assays was 0.05 IU/L, and the intra- and interassay CVs
were less than 4% and 5%, respectively, at LH concentrations at and
above the lowest standard concentration (0.6 IU/L of WHO Interna-
tional Reference Preparation 80/552).
Measures of muscle strength
Isometric grip strength was measured using an adjustable hand-held
dynamometer (JAMAR dynamometer) at the nondominant hand (16).
Each test was repeated three times, and the average was used in the
analyses. Leg or knee extensor strength (LES) was measured as de-
scribed previously (17, 18) using the Hoggan MicroFET hand-held dy-
namometer. To obtain one main outcome measurement for leg extensor
strength, maximum LES (maxLES) was defined as the maximum
strength for the right or left leg, whichever is largest, in a position of 120°
extension. Statistical analyses were based on the physical unit momen-
tum [Newton meters (Nm)], obtained by multiplying the maximum
strength (in Nm) and the distance of the dynamometer to the knee joint
(in meters).
Bone mineral density and body composition measurements
Total body bone mineral density was measured using dual energy
x-ray absorptiometry (Lunar Corp., Madison, WI), as were hip bone
mineral densities at the femoral neck, trochanter, and Ward’s triangle.
In addition, total and trunk lean body mass and fat mass were measured
(19). Quality assurance for dual energy x-ray absorptiometry, including
calibration, was performed routinely every morning, using the standard
provided by the manufacturer.
Height and weight were measured in standing position without
shoes. Body mass index (BMI) was calculated as the weight in kilograms
divided by the square of the height in meters.
Physical performance
Lower extremity function, or physical performance score, was as-
sessed as described by Guralnik et al. (20), including measurements of
standing balance, walking speed, and ability to rise from a chair. Three
tests of standing balance were considered in hierarchical difficulty in
assigning a single score of 0–4 for standing balance. For the 8-ft walk
and repeated chair stands, those who could not complete the task were
assigned a score of 0. Those completing the task were assigned scores
of 1–4, corresponding to the quartiles of time needed to complete the
task, with the fastest times scoring as 4. A summary performance scale
was created by summing the category scores for the walking, chair stand,
and balance test.
Satisfaction in performing activities of daily living was assessed by
using a self-administered questionnaire from the Stanford Modified
Health Assessment Questionnaire (MHAQ), as described by Pincus et al.
(21), in which high score means low ability. The final score of the MHAQ
was not normally distributed. Analyses were performed after logarith-
mic transformation.
Data analyses
Results were expressed, unless otherwise stated, as the mean and sd
with the interquartile range. Relations between variables were assessed
using linear regression for continuous variables and logistic regression
for binary variables and were described as the linear regression coef-
ficient (b) and its se. Multiple regression analysis was used to adjust for
age and BMI as well as to assess the contributions of different inde-
pendent variables to the dependent variable. Correlations between vari-
ables were assessed using Pearson’s correlation coefficient r. Pearson x2
test was used to assess differences in variables between groups. If not
mentioned otherwise, all analyses were performed after adjustment
for age.
Results
Descriptive data of all parameters measured are shown in
Table 1. Their relations with age are shown in Table 2. LH
was significantly positively related with age and SHBG (Ta-
ble 3). An inverse relation existed between LH and the dif-
ferent T measurements (Fig. 1 and Table 3). Albumin and
leptin levels were not related with LH.
T and frailty
T was independently related to muscle strength, bone
mineral density, and fat mass. Linear regression coeffi-
cients for relations between non-SHBG-T and maxLES,
respectively, and total body bone mineral density were b
5 1.93 6 0.53 and b 5 0.01 6 0.002 (P , 0.001). Total body
TABLE 1. Descriptive data of the study population (n 5 403)
Mean 6 SD Interquartilerange
Age (yr) 77.8 6 3.58 75–80
BMI 25.45 6 3.04 23.32–27.25
Total T (nmol/L) 8.83 6 2.98 7.19–10.66
SHBG (nmol/L) 31.5 6 14.4 23.2–37.5
Non-SHBG-bound T (nmol/L) 5.68 6 1.89 4.62–6.76
LH (IU/L) 9.38 6 8.41 4.57–11.15
Leptin (mg/L) 5.35 6 4.21 2.45–6.90
Albumin (g/L) 45.6 6 2.76 43.8–47.5
IGS (kg) 34.3 6 6.9 30.0–38.7
MaxLES (Nm) 103.2 6 20.9 89.4–117.1
Total fat mass (kg) 21.2 6 6.4 17.4–24.5
Total lean mass (kg) 51.7 6 5.6 47.8–55.5
Total body BMD (g/cm2) 1.17 6 0.10 1.11–1.23
Femoral neck BMD (g/cm2) 0.88 6 0.14 0.78–0.97
Femoral ward BMD (g/cm2) 0.72 6 0.16 0.60–0.82
Femoral trochanter BMD (g/cm2) 0.85 6 0.15 0.76–0.94
Physical performance (points) 8.45 6 2.43 7–10
MHAQ (points) 10.70 6 4.30 8–12
IGS, Isometric grip strength; MaxLES, maximum leg extensor
strength; MHAQ, Modified Health Assessment Questionnaire. Nor-
mative values for healthy young men are 9.72–30.54 nmol/L for total
T, 10–55 nmol/L for SHBG, and 3.6–17.1 IU/L for LH.
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fat mass decreased 0.53 6 0.15 kg/nmolzL non-SHBG-T. T
was not related to lean mass or the physical performance
score.
LH and frailty
The relations between LH and the measures of frailty are
shown in Table 3. LH was inversely related to maxLES (Fig.
2a). LH was also inversely related to lean mass, independent
of maxLES (Fig. 2b). LH was not associated with bone min-
eral density or fat mass in the group as a whole. A positive
relation existed between LH and MHAQ. MHAQ and
maxLES were strongly related, but the relation between LH
and MHAQ was independent of maxLES. Subjects with LH
levels in the highest quartile had 10.1% lower maxLES values
and 18.7% higher MHAQ values compared to subjects with
LH levels in the lowest quartile (after adjustment for age and
BMI).
Because we demonstrated that low T levels were accom-
panied by reduced muscle strength, a multiple regression
analysis was performed including LH and T. Both T (TT and
non-SHBG-T) and LH were significantly, but independently,
related to maxLES and isometric grip strength. Multiple re-
gression coefficients of the relations between maxLES and,
respectively, LH and non-SHBG-T were b 5 20.29 6 0.13
(P 5 0.03) and b 5 1.42 6 0.56 (P 5 0.01). Non-SHBG-T and
LH were also both related to MHAQ. However, in a multiple
regression analysis including LH and non-SHBG-T, only LH
remained significantly inversely related to MHAQ (b 5
0.007 6 0.002; P , 0.001 and b 5 20.008 6 0.009; P 5 0.40,
respectively).
LH variants
The heterozygote form of the LH variant was present in
12.5% (50 men) in this study population of elderly men. Mean
concentrations of TT, non-SHBG-T, LH, SHBG, leptin, and
albumin were not different in the wild-type LH group com-
pared with those in the heterozygote LH variant group. The
homozygote form of the LH variant was present in only 2
subjects (0.5%). Their TT values were 6.32 and 9.97 nmol/L.
FIG. 1. Relation between TT and LH (logarithmically transformed) of wild-type LH variant subjects, heterozygote LH variant subjects, and
homozygote LH variant subjects.
TABLE 2. Relationship between age and the hormones and the
characteristics of frailty
Age (yr; b 6 SE) P value
LH (IU/L) 0.06 6 0.01 ,0.001
Total T (nmol/L) 20.04 6 0.04 0.37
SHBG (nmol/L) 0.92 6 0.20 ,0.001
Non-SHBG-bound T (nmol/L) 20.07 6 0.03 0.01
Leptin (mg/L) 20.02 6 0.01 0.04
Albumin (g/L) 20.07 6 0.04 0.06
The b coefficient denotes changes in unit per year. For example, LH
increases 0.06 IU/Lzyr.
TABLE 3. Associations of LH with hormones, SHBG, albumin,
and characteristics of frailty
LH (IU/L; n 5 403;
b 6 SE) P value
Hormones (dependent variables)
Total T (nmol/L) 20.12 6 0.02 ,0.001
SHBG (nmol/L) 0.31 6 0.09 ,0.001
Non-SHBG-bound T (nmol/L) 20.09 6 0.01 ,0.001
Leptin(log) (mg/L) 0.002 6 0.005 0.63
Albumin (g/L) 20.002 6 0.02 0.91
Characteristics of frailty (dependent variables)
MaxLES (Nm) 20.41 6 0.12 ,0.001
IGS (kg) 20.09 6 0.04 0.03
Lean mass (kg) 20.11 6 0.09 ,0.001
Fat mass (kg) 20.03 6 0.04 0.43
TBBMD (g/cm2) 20.0005 6 0.005 0.38
PPS (points) 20.001 6 0.001 0.17
MHAQ(log) (points) 0.01 6 0.002 ,0.001
b denotes linear regression coefficient. For example, total T de-
creases 0.12 nmol/L per IU/L LH. Maximum leg extensor strength
(MaxLES), isometric grip strength (IGS), total body bone mineral
density (TBBMD), and Modified Health Assessment Questionnaire
(MHAQ) are also adjusted for body mass index.
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The relations between LH and T and age, respectively,
were not different in the two LH groups (Table 4).
None of the characteristics of frailty was different in the
heterozygote LH variant group compared to the wild-type
LH group. Mean values of the measures of frailty in the two
variant LH homozygote individuals were also within the
ranges of the other groups. The relations between LH, on the
one hand, and the different measures of frailty, on the other,
FIG. 2. Relation between LH in inter-
nationsl units per L and maxLES in Nm
(a) and lean body mass in kilograms (b).
Coef, Coefficient of linear regression.
TABLE 4. Age-adjusted linear regression analysis between LH and hormones, respectively, and characteristics of frailty in the wild-type
LH group and in the heterozygote LH variant group
Dependent Wild-type LH (n 5 347; b 6 SE) P Heterozygote LH variant (n 5 50;
b 6 SE) P
Hormones and SHBG
Age (yr) 0.44 6 0.11 ,0.001 1.73 6 0.39 ,0.001
BMI 20.05 6 0.02 0.02 0.06 6 0.04 0.14
Total T (nmol/L) 20.11 6 0.02 ,0.001 20.16 6 0.04 ,0.001
Non-SHBG-bound T (nmol/L) 20.0004 6 0.0001 ,0.001 20.0005 6 0.0001 ,0.001
SHBG (nmol/L) 0.45 6 0.10 ,0.001 0.05 6 0.13 0.69
Leptin(log) (mg/L) 20.004 6 0.006 0.46 0.03 6 0.01 0.02
Characteristics of frailty
MaxLES (Nm) 20.49 6 0.14 ,0.001 20.46 6 0.28 0.11
IGS (kg) 20.09 6 0.05 0.05 20.15 6 0.11 0.17
Lean mass (kg) 20.16 6 0.04 ,0.001 0.022 6 0.070 0.75
Fat mass (kg) 20.03 6 0.04 0.43 0.23 6 0.07 0.001
TBBMD (g/cm2) 20.0001 6 0.001 0.92 20.002 6 0.001 0.19
PPS (points) 20.001 6 0.001 0.26 20.001 6 0.001 0.26
MHAQ(log) (points) 0.006 6 0.002 0.007 0.012 6 0.004 0.004
b, Linear regression coefficient. Maximum leg extensor strength (MaxLES), isometric grip strength (IGS), total body bone mineral density
(TBBMD), physical performance (PPS), and Modified Health Assessment Questionnaire are also adjusted for BMI.
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in the two LH variant groups are shown in Table 4. Inter-
estingly, LH was positively associated with fat mass and
leptin only in the heterozygote LH variant group. This re-
mained after adjustment for T (TT or non-SHBG-T).
Discussion
In an independently living population of healthy elderly
men, LH significantly increased with age. This gonadotropin
was inversely associated with T (TT and non-SHBG-T). LH
was independent of T, negatively related to several charac-
teristics of frailty, i.e. maxLES and lean mass, and positively
related to self-reported disability. In this population, 12.5%
were heterozygous for the LH variant allele. In the hetero-
zygote LH variant subjects, but not in those with wild-type
hormone, LH was positively related to fat mass and leptin.
Conflicting results have been reported concerning the
question of whether LH increases with age or remains rel-
atively stable (22, 23). One reason may be that the aging-
induced decrease in T is primarily testicular in some men,
mainly due to hypothalamo-pituitary insufficiency in others
and of mixed origin in a third group. In our study population,
LH increased significantly with age. The inverse relation we
found between LH and TT could be due to the rather low T
levels of the subjects in our study population. It is likely that
in subjects with low T levels, LH cannot increase T, because
of a primary disturbance of Leydig cell function.
The strong inverse relation of LH with muscle strength,
lean mass, and self-reported disability, which is independent
of T, suggests that LH also reflects the process of frailty. This
association has not been described previously. Our obser-
vation might imply that LH monitors androgen effects in a
different manner than T, probably because LH levels reflect
the sum of systemic T levels as well as locally produced
5a-dihydrotestosterone and estrogens, which are produced
via the local conversion of T. We did measure estradiol in this
study; however, this hormone could not explain the inde-
pendent relation of LH to the characteristics of frailty. The
mechanism of this relationship remains to be elucidated.
Previously, a common variant form of LH has been de-
tected in apparently healthy individuals due to the point
mutation-based substitutions described above. There is a
large variation in the common frequency of this polymor-
phism in different populations (0–50%) (15), and presently
research is underway to investigate its possible clinical cor-
relates. The prevalence of heterozygozity for the LH variant
allele in the current cohort of subjects is in agreement with
frequencies measured previously in The Netherlands, which
found a mean frequency of 14.3% (95% confidence interval,
5.7–22.9) in 63 men and women aged 15 yr and older (15). The
stability of the prevalence across age groups suggests that
there is no selection regarding survival of the LH variant. It
has been proposed that the in vivo bioactivity of the LH
variant is lower than that of the wild-type hormone due to
its shorter circulatory half-time (9, 10). On the other hand,
this may be compensated for by the higher bio/immuno ratio
of the variant hormone at the LH target cell level (8, 24).
Neither the mean T, SHBG, and leptin levels nor the mean
characteristics of frailty values differed between subjects
with the wild-type LH and subjects with the heterozygote
form of the LH variant. However, from subjective assessment
of the findings presented in Fig. 1, it appears that the pro-
portion heterozygous for the LH variant was relatively large
in a group of subjects with low T and high LH concentrations.
This is compatible with a reduced in vivo bioactivity of LH
in the heterozygous individuals. Further, we observed dif-
ferences in the relations between LH and leptin as well as fat
mass between subjects with the different LH forms. The
nature of these differences remains to be explained.
In conclusion, in independently living elderly men, LH
increases with age and is inversely related to T. The observed
relation between LH and frailty, independent of T, suggests
that LH levels reflect the overall serum androgen activity in
a different manner from T, possibly reflecting the combined
effect of estrogen and androgen feedback action at the hy-
pothalamic-pituitary level. The hormone levels and the de-
gree of frailty are not different in the wild-type and hetero-
zygote LH groups. However, a difference in biological
response between the two LH forms is suggested, as a dif-
ference exists in the relation between LH and fat mass, re-
spectively, and leptin in the heterozygote LH variant subjects
vs. the wild-type LH subjects.
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